biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics is a biotech organization headquartered in Wilmington, USA. It trades on NYSE under ticker IKT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Pulmonary Arterial Hyperten
Phase 1 · small molecule · CML
Imatinib mesylate (internal code IkT-001Pro-501) is an oral small-molecule tyrosine kinase inhibitor developed by Inhibikase Therapeutics for chronic myeloid leukemia (CML). The drug is a well-established therapeutic agent with multiple approved generic and branded formulations in the United States, marketed under vari
Internal code IkT-001Pro-501
Imatinib mesylate (internal code IkT-001Pro-501) is an oral small-molecule tyrosine kinase inhibitor developed by Inhibikase Therapeutics for chronic myeloid leukemia (CML). The drug is a well-established therapeutic agent with multiple approved generic and branded formulations in the United States, marketed under various brand names and manufactured by numerous pharmaceutical companies including Novartis, Teva, Mylan, and others. Inhibikase's Phase 1 program (NCT05623774) completed as of November 2025, representing the sponsor's clinical development activity in this indication. Imatinib mesylate has been approved in the US across multiple application types, including the original new drug application (NDA021335, NDA021588) and numerous abbreviated new drug applications (ANDAs) spanning from 2004 through recent years, reflecting its status as a foundational CML therapy. The competitive landscape includes multiple tyrosine kinase inhibitors at various development stages, including second-generation agents such as nilotinib (Tasigna), dasatinib, bosutinib, and third-generation agents like asciminib and ponatinib. Inhibikase's specific development strategy and rationale for conducting Phase 1 work on an established molecule are not disclosed in available data.
Chronic myeloid leukemia remains a significant hematologic malignancy affecting thousands of patients globally. While imatinib mesylate revolutionized CML treatment upon its introduction and remains a standard-of-care first-line therapy, ongoing clinical research continues to explore optimization of dosing, formulation, safety profiles, and patient populations. The competitive CML market includes multiple approved tyrosine kinase inhibitors with varying efficacy profiles, resistance patterns, and tolerability characteristics. Patients with CML benefit from multiple therapeutic options, yet treatment resistance, intolerance, and disease progression remain clinical challenges. Inhibikase's Phase 1 program may represent investigation of novel formulations, dosing strategies, or patient populations not yet disclosed. The market for CML therapeutics remains substantial given the chronic nature of the disease and the requirement for long-term therapy. Multiple manufacturers produce imatinib mesylate generically, indicating mature market competition and established clinical utility. Understanding the specific unmet medical need addressed by Inhibikase's program requires additional disclosure of the trial's primary objectives and patient population characteristics.
Drug Class: Tyrosine kinase inhibitor (TKI), small-molecule.
Modality: Oral small-molecule.
Route of Administration: Oral.
Mechanism of Action: Not disclosed in available data; however, imatinib mesylate is established as a BCR-ABL tyrosine kinase inhibitor.
Target: Not disclosed in available data; established target is BCR-ABL fusion protein.
Related Therapies: Second-generation TKIs (nilotinib, dasatinib, bosutinib) and third-generation TKIs (asciminib, ponatinib) for CML.
First Approval: Imatinib mesylate was approved by the FDA under NDA021335 and NDA021588; exact approval dates not disclosed in provided data.
Patent Status: Not disclosed in available data.
Also known as: BCR-ABL Positive chronic myelogenous leukaemia, BCR-ABL Positive chronic myelogenous leukemia, CML, CML - chronic myelogenous leukaemia, CML - chronic myelogenous leukemia, chronic granulocytic leukemia
Prevalence: Point prevalence: 1-9 / 100 000 (Europe) — source: Orphanet, validated.
A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.
ClinicalTrials.gov lists 265 registered studies for Chronic Myeloid Leukemia (AACT aggregate).
Phase breakdown: NA (95), PHASE2 (81), PHASE1 (33), PHASE3 (20), PHASE1/PHASE2 (19), PHASE4 (8), PHASE2/PHASE3 (5), EARLY_PHASE1 (4)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011996), Orphanet — chronic myeloid leukemia, NCT00001144, NCT00001432, NCT00038675, NCT00061581, NCT00067028, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 completion
Inhibikase Therapeutics Phase 1 program (IkT-001Pro-501, NCT05623774) for imatinib mesylate in CML completed.
The CML therapeutic landscape includes multiple approved and investigational tyrosine kinase inhibitors. Novartis maintains a substantial presence with approved agents Glivec (imatinib) and Tasigna (nilotinib), alongside investigational programs including asciminib and ponatinib in Phase 2–3 development. Bristol-Myers Squibb markets dasatinib, a second-generation TKI in Phase 2 development per the data. Takeda has ponatinib in Phase 2 development. Enliven Therapeutics is developing ELVN-001, a Phase 1 small-molecule program. Multiple manufacturers produce generic imatinib mesylate (Amneal, Apotex, Teva, Mylan, Sun Pharma, Dr. Reddy's, Natco, Hikma, and others), indicating a mature, competitive generic market. Inhibikase's Phase 1 program represents a late-stage entry into an established therapeutic area with multiple approved options and active development pipelines from larger pharmaceutical companies. The competitive advantage of Inhibikase's program, if any, is not disclosed in available data.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Glivec 100 mg hard capsules, Tasigna 150 mg hard capsules | Fondazione Telethon ETS | small_molecule | approved |
| Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules | Novartis Pharmaceuticals | small_molecule | phase_3 |
| ASCIMINIB HYDROCHLORIDE, ASCIMINIB | Novartis Pharmaceuticals | small_molecule | phase_3 |
| Scemblix 40 mg film-coated tablets | Novartis Pharmaceuticals | small_molecule | phase_2 |
| Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB | Novartis Pharmaceuticals | small_molecule | phase_2 |
| ponatinib - Phase 1 | Takeda | small_molecule | phase_2 |
| DASATINIB, Dasatinib, dasatinib, dasatinib | Bristol-Myers Squibb Australia Pty Ltd | small_molecule | phase_2 |
| Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | phase_2 |
| ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib | Novartis Pharmaceuticals | small_molecule | phase_2 |
| Imatinib/Acetaminophen | Novartis Pharmaceuticals | small_molecule | phase_1 |
| ELVN-001 | Enliven Therapeutics | small_molecule | phase_1 |
| HS-10382(Part 1: Dose escalation) | Jian Li | small_molecule | phase_1 |
| PONATINIB HYDROCHLORIDE | — | Bcr/Abl fusion protein inhibitor | Approved |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE | — | Tyrosine-protein kinase ABL inhibitor | Approved |
| INTERFERON ALFA-2B | — | Interferon alpha/beta receptor agonist | Approved |
| IMATINIB MESYLATE | — | Platelet-derived growth factor receptor beta inhibitor | Approved |
| HYDROXYUREA | — | Ribonucleoside-diphosphate reductase RR1 inhibitor | Approved |
| DASATINIB | — | SRC inhibitor | Approved |
| BOSUTINIB MONOHYDRATE | — | Bcr/Abl fusion protein | Approved |
| ASCIMINIB HYDROCHLORIDE | — | Bcr/Abl fusion protein inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States FDA Status: Imatinib mesylate is approved in the US under multiple regulatory pathways. Original approvals include NDA021335 and NDA021588 (Novartis). Abbreviated new drug applications (ANDAs) have been approved for multiple generic manufacturers: ANDA078340, ANDA079179, ANDA204285, ANDA204644, ANDA205990, ANDA206547, ANDA207495, ANDA207586, ANDA207818, ANDA208302, ANDA208429, ANDA210658, ANDA212135, ANDA212193, ANDA212773, and ANDA212975. Most recent ANDA approvals span recent years, confirming ongoing generic market activity.
European Medicines Agency (EMA): Not disclosed in available data.
Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Not disclosed in available data.
National Medical Products Administration (NMPA, China): Not disclosed in available data.
Loss of Exclusivity (LOE) Date: Not disclosed in available data.
Imatinib mesylate is a tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia (CML) and other BCR-ABL-positive malignancies. It is a standard-of-care first-line therapy for CML.
Yes, imatinib mesylate is approved by the FDA under multiple regulatory pathways, including original new drug applications (NDA021335, NDA021588) and numerous abbreviated new drug applications (ANDAs) for generic formulations.
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, a constitutively active kinase that drives CML pathogenesis. By inhibiting this kinase, imatinib suppresses malignant cell proliferation.
Multiple manufacturers produce imatinib mesylate, including Novartis (original developer), Teva, Mylan, Sun Pharma, Dr. Reddy's, Amneal, Apotex, Natco, Hikma, and others. Both branded and generic formulations are available.
Inhibikase Therapeutics is conducting a Phase 1 clinical trial (IkT-001Pro-501, NCT05623774) for imatinib mesylate in CML, which completed as of November 2025. The specific clinical rationale and development strategy are not yet disclosed.
NCT05623774 is the Phase 1 trial conducted by Inhibikase Therapeutics for imatinib mesylate in CML. The trial completed as of November 6, 2025, but detailed results have not yet been reported.
Inhibikase's Phase 1 program for imatinib mesylate completed as of November 2025. The next development milestone and planned progression to Phase 2 have not been disclosed.
Competing CML therapies include second-generation tyrosine kinase inhibitors (nilotinib, dasatinib, bosutinib) and third-generation agents (asciminib, ponatinib), all developed by companies including Novartis, Bristol-Myers Squibb, and Takeda.
Yes, imatinib mesylate is available in multiple generic formulations from numerous manufacturers, reflecting its status as an established therapy with expired patent exclusivity in many markets.
Imatinib mesylate is administered orally, typically as a tablet or capsule formulation.
Imatinib mesylate inhibits the BCR-ABL tyrosine kinase, the constitutively active fusion protein that drives chronic myeloid leukemia pathogenesis, thereby suppressing malignant cell proliferation.
No partner or licensee information is disclosed for Inhibikase's imatinib mesylate program in the available data.
Projected peak sales figures are not disclosed in available data.
Exact approval dates are not disclosed in available data; however, imatinib mesylate was approved under NDA021335 and NDA021588, with numerous generic approvals (ANDAs) following.
Imatinib mesylate is classified as a tyrosine kinase inhibitor (TKI), a small-molecule targeted therapy for BCR-ABL-positive malignancies.
Information regarding other Inhibikase programs is not disclosed in the provided data; the focus is on the imatinib mesylate Phase 1 program.
Imatinib Mesylate → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Inhibikase Therapeutics' Phase 1 program for imatinib mesylate represents development activity in an established therapeutic area with mature competition and multiple approved options. The specific clinical rationale, patient population, and differentiation strategy are not disclosed. Completion of Phase 1 as of November 2025 suggests the program has advanced through initial safety and tolerability assessment, though next development steps are not yet disclosed.
Competitive Implications: Entry into the CML market by a smaller sponsor occurs in a landscape dominated by Novartis and other large pharmaceutical companies with established portfolios and ongoing pipeline development. Multiple generic manufacturers produce imatinib mesylate, indicating price competition and market maturity. Inhibikase's competitive advantage, if any, would likely depend on novel formulation, dosing optimization, or targeting of specific patient subpopulations—details not yet disclosed.
Future Catalysts: Disclosure of Phase 1 results, announcement of Phase 2 initiation (if planned), and clarification of the program's clinical and commercial rationale. Regulatory interactions with the FDA regarding development pathway would be significant catalysts.
Expected Milestones: Next milestone date and label not yet disclosed in available data.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.